デフォルト表紙
市場調査レポート
商品コード
1471238

粒子線治療市場:治療タイプ、コンポーネント、構成、がんタイプ、エンドユーザー別-2024~2030年の世界予測

Particle Therapy Market by Therapy Type (Heavy Ion Therapy, Proton Therapy), Component (Product, Service), Configuration, Cancer Type, End-User - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
粒子線治療市場:治療タイプ、コンポーネント、構成、がんタイプ、エンドユーザー別-2024~2030年の世界予測
出版日: 2024年04月17日
発行: 360iResearch
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

粒子線治療市場規模は、2023年に7億7,241万米ドルと推定され、2024年には8億3,150万米ドルに達し、CAGR 7.94%で2030年には13億1,887万米ドルに達すると予測されています。

粒子線治療は、より広範な治療技術の特定のセグメントを形成しています。主に、粒子線治療技術の世界の商業化、流通、応用に焦点を当てています。粒子線治療は、陽子や中性子などの荷電粒子や非荷電粒子を制御された環境内で利用し、患者の体内のがん細胞を標的にして除去します。精度を確保する上でこの治療法が有効であることが、主に市場の需要と成長の原動力となっています。がん治療における高度な治療に対するニーズの高まりや、臨床試験における粒子線治療の採用の増加、迅速で非侵襲的、痛みの少ない処置は、この市場成長の推進に大きく寄与しています。一方、粒子線治療に対する保険適用は限られており、粒子線治療の放射線被曝に伴うリスクもあるため、その利用は制限され、市場成長の妨げとなっています。しかし、複数のベンダーがより高度でコンパクトな粒子線治療システムを開発し、精度の向上と潜在的な副作用の最小化に注力しています。さらに、現在進行中の陽子線治療研究プログラムや荷電粒子線治療の技術的進歩は、粒子線治療拡大の無数の機会を生み出しています。

主要市場の統計
基準年[2023年] 7億7,241万米ドル
予測年[2024年] 8億3,150万米ドル
予測年[2030年] 13億1,887万米ドル
CAGR(%) 7.94%

治療タイプ:陽子線治療は、周辺組織へのダメージのリスクが低いため、消費者に好まれています。

重粒子線治療では、炭素などの高密度に電離した原子を用いて、がん細胞に正確なダメージを与えます。この技術により、周囲の健康な組織へのダメージは最小限に抑えられます。この治療法は放射線抵抗性の腫瘍に有効で、従来の放射線治療より優れています。陽子線治療は、周囲の組織や臓器への損傷を制限する性質があるため、特に小児科でますます好まれるようになっており、重要な臓器の近くに腫瘍がある患者に大きな違いをもたらしています。重粒子線治療は、放射線抵抗性腫瘍に対する有望な解決策を提供し、陽子線治療は、周辺組織への損傷のリスクが少ないため、しばしば小児がん患者に好まれます。

コンポーネント:重要臓器近傍の固形腫瘍の治療において、その精度の高さからコンポーネント製品の利用が増加しています。

粒子線治療製品は、主に対象の粒子ビームを照射する装置を構成します。これにはサイクロトロン、シンクロサイクロトロン、シンクロトロンなどの装置が含まれます。サイクロトロンは荷電粒子を高エネルギーまで加速するために利用されます。シンクロサイクロトロンは、加速電界の周波数を変えることで、サイクロトロンの周波数制限を克服するように設計されています。そのため、高エネルギービームを効果的かつ正確に供給することができ、粒子線治療に最適です。シンクロトロンは粒子加速器ですが、加速される粒子のエネルギーをより制御できるため、粒子線治療に最適です。深部腫瘍や複雑な形態の腫瘍の治療によく利用されています。粒子線治療は、腫瘍細胞に高線量の放射線を正確に照射し、医療施設の特定のニーズや状況に応じて、それぞれが独自のメリットを提供するさまざまなシステムがあります。サービスセグメントには、粒子線治療システムに関する設置、メンテナンス、トレーニング、コンサルティングサービスが含まれます。一方、がん患者の流入が多く、粒子線治療ユニットをサポートするインフラを持つ医療機関では、製品コンポーネントの需要がより切迫しています。サービスコンポーネントの需要は、医療機関が粒子線治療ユニットの開発の初期段階にある、あるいは開発を計画している国々でより高いです。

構成:より多くの患者を同時に治療するマルチルームシステムの可能性

粒子線治療のマルチルームシステムは、複数の治療室を組み込むことで、より多くの患者を同時に治療することができます。このようなシステムは、患者の流れが速く、複雑な症例にも対応でき、粒子加速器施設の利用効率を最大化できるため、大規模医療施設にとって非常に有益です。シングルルームシステムは、粒子線治療の領域に踏み出そうとしている小規模医療施設にとって理想的な選択肢です。コンパクトな設計と比較的単純なロジスティックスにより、一般的に導入と管理が容易です。それに比べ、マルチルームシステムは、より多くの患者を同時に治療し、複雑な症例に対応するのに有益であり、その導入には、より高い初期投資と運用の複雑さが要求されます。一方、シングルルームシステムは、コンパクトな設計と管理しやすいロジスティックスにより、導入と運用が容易であるため、粒子線治療に取り組み始めた小規模な医療施設に適しています。

がんタイプ:頭頸部がんへの粒子線治療の使用は、健常組織へのリスク軽減により拡大中

高集束放射線を提供する粒子線治療は、特に再発性・進行性の乳がん患者に顕著な効果をもたらしています。頭頸部がんに対する粒子線治療は、解剖学的に複雑な部位であるため、有望な結果を示しています。粒子線治療の正確で高線量の放射線は、腫瘍周辺の健康な組織への過剰な放射線のリスクを最小限に抑えます。肺がんは、従来の放射線治療に対する抵抗性で悪名高いが、粒子線治療によって有望な治療結果が得られています。粒子線治療は小児がんの治療にもかなり有効で、従来の放射線治療に通常伴う長期的な副作用を軽減します。前立腺がん治療では、粒子線治療の効果的で精密な放射線技術により、治療効果が飛躍的に向上しました。それに比べ、粒子線治療は頭頸部がん治療のセグメントで新たな夜明けとして登場し、様々な病態と闘う患者に希望を与えています。

エンドユーザー:質の高い医療を提供するために、病院や臨床現場で粒子線治療が果たす役割は大きいです。

外来手術センター(ASC)により、外科医は効率的で質の高い治療を低コストで提供できます。粒子線治療では、これらのセンターは、がんが明確で、数回の治療で済むようなケースに対応しています。病院やクリニックは、より包括的な治療を提供し、さまざまながんの症例に対応しています。陽子線治療と重粒子線治療の両方を提供し、より複雑な問題を含むさまざまながんを治療します。これらの施設には、高度な粒子線治療装置を備えた大規模な治療施設があります。外来手術センターは、その運営の性質上、あまり複雑でない症例に最適なコンパクトで合理的なデザインを採用し、限られたスペースで効率性を追求しています。病院・クリニックは、単純な症例から複雑な症例まで様々な症例に対応できるよう、より強固な治療機能を提供しています。

地域別洞察

アメリカでは、粒子線治療のニーズが一貫して伸びています。技術革新は頻繁に行われており、民間・公的機関の両方から大きな支援を受けています。この地域が最も大きな市場シェアを占めているのは、広範な調査活動と、治療イノベーションを対象とする投資家が資金を提供する数多くの新興企業の台頭によるものです。欧州、中東、アフリカ地域では、欧州が粒子線治療で手ごわい成長を示しているが、その主要理由は、さまざまな種類のがんの罹患率が上昇していることと、リスクを抱える高齢者人口が増加していることです。さらに、様々な政府や組織からの医療への資金援助が増加し、確立された医療施設と相まって、この技術が広く採用されるようになっています。中東・アフリカ諸国も、主に医療費の増加と医療インフラ強化への取り組みの増加により、有望な成長を示しています。アジア太平洋では、いくつかの国ががん治療に粒子線治療を採用しています。このような進歩の要因としては、がん有病率の増加、急速な都市化、継続的な経済状況の改善などが挙げられます。アジア太平洋には膨大な人口基盤があり、医療インフラの改善やがん研究・治療に対する政府資金の増加と相まって、アジア太平洋は粒子線治療の急成長市場となっています。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスは粒子線治療市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を記載しています。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます。フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、粒子線治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、このセグメントの競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています。

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を記載しています。

4.競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発とイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を記載しています。

本レポートは、以下のような主要な質問に対応しています。

1.粒子線治療市場の市場規模と予測は?

2.粒子線治療市場の予測期間中に投資を検討すべき製品、用途は何か?

3.粒子線治療市場の技術動向と規制枠組みは?

4.粒子線治療市場における主要ベンダーの市場シェアは?

5.粒子線治療市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • がん治療における先進的治療法の必要性
      • 臨床試験における粒子線治療の採用増加
      • 世界中で粒子線治療センターが増加
    • 抑制要因
      • 粒子線治療の機器と手順のコストが高く、粒子線治療の保険適用範囲が限られている
    • 機会
      • 進行中の陽子線治療調査プログラム
      • 荷電粒子線治療の技術的進歩と個別化されたがん治療戦略の実現
    • 課題
      • 粒子線治療放射線被曝に関連するリスク
  • 市場セグメンテーション分析
    • 治療タイプ:周囲の組織への損傷リスクが低いため、消費者は陽子線治療を好む
    • コンポーネント:高い精度により、重要な臓器の近くの固形腫瘍の治療に製品コンポーネントの利用が増加
    • 構成:多数の患者を同時に治療できるマルチルームシステムの可能性
    • がんタイプ:健康な組織へのリスクが低減したため、頭頸部がんに対する粒子線治療の使用が拡大
    • エンドユーザー:病院や医療機関が質の高いケアを提供しようと努める中で、粒子線治療が果たす重要な役割
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 粒子線治療市場:治療タイプ別

  • イントロダクション
  • 重粒子線治療
  • 陽子線治療

第7章 粒子線治療市場:コンポーネント別

  • イントロダクション
  • 製品
  • サービス

第8章 粒子線治療市場:構成別

  • イントロダクション
  • マルチルームシステム
  • シングルルームシステム

第9章 粒子線治療市場:がんタイプ別

  • イントロダクション
  • 乳がん
  • 頭頸部がん
  • 肺がん
  • 小児がん
  • 前立腺がん

第10章 粒子線治療市場:エンドユーザー別

  • イントロダクション
  • 外来手術センター
  • 病院・クリニック

第11章 南北アメリカの粒子線治療市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋の粒子線治療市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカの粒子線治療市場

  • イントロダクション
  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • 市場シェア分析、2023年
  • FPNVポジショニングマトリックス、2023年
  • 競合シナリオ分析
  • 戦略分析と提言

第15章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. PARTICLE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. PARTICLE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PARTICLE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PARTICLE THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PARTICLE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PARTICLE THERAPY MARKET DYNAMICS
  • FIGURE 7. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. PARTICLE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. PARTICLE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PARTICLE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PARTICLE THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PARTICLE THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PARTICLE THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PARTICLE THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HEAVY ION THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HEAVY ION THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PROTON THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PROTON THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CYCLOTRONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CYCLOTRONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SYNCHROCYCLOTRONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SYNCHROCYCLOTRONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SYNCHROTRONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SYNCHROTRONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SERVICE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SERVICE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PARTICLE THERAPY MARKET SIZE, BY MULTI-ROOM SYSTEM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PARTICLE THERAPY MARKET SIZE, BY MULTI-ROOM SYSTEM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SINGLE-ROOM SYSTEM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SINGLE-ROOM SYSTEM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PARTICLE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PARTICLE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PARTICLE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PARTICLE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PEDIATRIC CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PEDIATRIC CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL PARTICLE THERAPY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL PARTICLE THERAPY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 126. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 146. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 148. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. CHINA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 156. CHINA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 157. CHINA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 158. CHINA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 159. CHINA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 160. CHINA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 161. CHINA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. CHINA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. CHINA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. CHINA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. INDIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. INDIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. INDIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 168. INDIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 169. INDIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 170. INDIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 171. INDIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 172. INDIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 173. INDIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. INDIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. INDIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. INDIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. INDONESIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. INDONESIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. INDONESIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 180. INDONESIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 181. INDONESIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 182. INDONESIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 183. INDONESIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 184. INDONESIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 185. INDONESIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. INDONESIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. INDONESIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 188. INDONESIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 189. JAPAN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. JAPAN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. JAPAN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 192. JAPAN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 193. JAPAN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 194. JAPAN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 195. JAPAN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 196. JAPAN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 197. JAPAN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. JAPAN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. JAPAN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 200. JAPAN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 201. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 204. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 205. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 206. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 207. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 208. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 209. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 216. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 218. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 220. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 228. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 229. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 230. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 231. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 232. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 233. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 240. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. TAIWAN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. TAIWAN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. TAIWAN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 252. TAIWAN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 253. TAIWAN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 254. TAIWAN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 255. TAIWAN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 256. TAIWAN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 257. TAIWAN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. TAIWAN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. TAIWAN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 260. TAIWAN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 261. THAILAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. THAILAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. THAILAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 264. THAILAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 265. THAILAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 266. THAILAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 267. THAILAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 268. THAILAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 269. THAILAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. THAILAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. THAILAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. THAILAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. VIETNAM PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. VIETNAM PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. VIETNAM PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 276. VIETNAM PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 277. VIETNAM PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 278. VIETNAM PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 279. VIETNAM PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 280. VIETNAM PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 281. VIETNAM PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. VIETNAM PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. VIETNAM PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. VIETNAM PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 299. DENMARK PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. DENMARK PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. DENMARK PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 302. DENMARK PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 303. DENMARK PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 304. DENMARK PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 305. DENMARK PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 306. DENMARK PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 307. DENMARK PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 308. DENMARK PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 309. DENMARK PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 310. DENMARK PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 311. EGYPT PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. EGYPT PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. EGYPT PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 314. EGYPT PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 315. EGYPT PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 316. EGYPT PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 317. EGYPT PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 318. EGYPT PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 319. EGYPT PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. EGYPT PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. EGYPT PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 322. EGYPT PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 323. FINLAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. FINLAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. FINLAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 326. FINLAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 327. FINLAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 328. FINLAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 329. FINLAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 330. FINLAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 331. FINLAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 332. FINLAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 333. FINLAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 334. FINLAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 335. FRANCE PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 336. FRANCE PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 337. FRANCE PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 338. FRANCE PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 339. FRANCE PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 340. FRANCE PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 341. FRANCE PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 342. FRANCE PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 343. FRANCE PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 344. FRANCE PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 345. FRANCE PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 346. FRANCE PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 347. GERMANY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 348. GERMANY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 349. GERMANY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 350. GERMANY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 351. GERMANY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 352. GERMANY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 353. GERMANY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2023 (USD MILLION)
  • TABLE 354. GERMANY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2024-2030 (USD MILLION)
  • TABLE 355. GERMANY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 356. GERMANY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 357. GERMANY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 358. GERMANY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 359. ISRAEL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2023 (USD MILLION)
  • TABLE 360. ISRAEL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024-2030 (USD MILLION)
  • TABLE 361. ISRAEL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 362. ISRAEL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 363. ISRAEL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 364. ISRAEL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLIO
目次
Product Code: MRR-335201F2E2B6

[193 Pages Report] The Particle Therapy Market size was estimated at USD 772.41 million in 2023 and expected to reach USD 831.50 million in 2024, at a CAGR 7.94% to reach USD 1,318.87 million by 2030.

The particle therapy forms a specific segment of the broader therapeutical technology. Primarily, it focuses on the global commercialization, distribution, and application of particle therapy technologies. Particle therapy utilizes charged and uncharged particles, such as protons and neutrons, within a controlled environment to target and eliminate cancer cells inside a patient's body. The effectiveness of this therapy in ensuring precision mainly drives market demand and growth. The increasing need for advanced therapies in cancer treatment and the rising adoption of particle therapy in clinical trials, fast, non-invasive, and painless procedures significantly contribute to driving this market growth. In contrast, limited insurance coverage for particle therapy and risk associated with particle therapy radiation exposure limits their utilization and penetrates the market growth. However, several vendors are developing more advanced and compact particle therapy systems and focusing on enhancing precision and minimizing potential side effects. Moreover, ongoing proton therapy research programs and technological advancements in charged-particle therapy are creating a myriad of opportunities for particle therapy expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 772.41 million
Estimated Year [2024] USD 831.50 million
Forecast Year [2030] USD 1,318.87 million
CAGR (%) 7.94%

Therapy Type: Consumer preference for proton therapy as it provides a reduced risk of damage to surrounding tissues

Heavy ion therapy employs densely ionized atoms such as carbon to initiate precise damage to cancer cells. The technique results in minimal damage to surrounding healthy tissue. This therapy is effective on radio-resistant tumors, providing an edge over traditional forms of radiotherapy. Proton therapy is increasingly preferred, especially in pediatrics, due to its damage-limiting property for surrounding tissues and organs, making a significant difference to patients with tumors near critical organs. Heavy ion therapy provides a promising solution for radio-resistant tumors, and proton therapy is often preferred for pediatric cancer patients because of its reduced risk of damage to surrounding tissues.

Component: Rising utilization of product components for treating solid tumors near vital organs due to their high accuracy

Particle therapy products primarily constitute equipment that delivers the target's particle beams. This includes machines such as cyclotrons, synchrocyclotrons, and synchrotrons. Cyclotrons are utilized to accelerate charged particles to high energies. Synchrocyclotrons are designed to overcome the frequency limitation of cyclotrons by altering the frequency of the accelerating electric field. This makes them ideal for particle therapy due to their ability to deliver high-energy beams effectively and accurately. Synchrotrons are particle accelerators but demonstrate more control over the energy of the accelerated particles, making them an excellent choice for particle therapy. They are often utilized in treating deep-seated and complex-shaped tumors. Particle therapy delivers high doses of radiation precisely to tumor cells and comes in different systems where each offers unique benefits depending upon the specific needs and situations of the healthcare establishment. The services segment includes installation, maintenance, training, and consulting services related to particle therapy systems. In comparison, the requirement for a product component is more imminent in countries with health institutes experiencing an influx of cancer patients and having the infrastructure to support a particle therapy unit. The service component's demand is more in countries where healthcare organizations are in the early stages of developing or planning to develop a particle therapy unit.

Configuration: Potential of a multi-room system for treating a larger number of patients concurrently

A multi-room system in particle therapy incorporates multiple treatment rooms, thus allowing more patients to receive treatment concurrently. These systems are immensely beneficial for large healthcare establishments, owing to the faster patient flow, the ability to treat complex cases, and the efficiency in maximizing the usage of particle accelerator facilities. Single-room systems are the ideal choice for smaller healthcare facilities that are starting to venture into the realm of particle therapy. They are generally easier to implement and manage due to the compact design and relatively simpler logistics. In comparison, multi-room systems are beneficial in treating a larger number of patients concurrently and cater to complex cases, and their implementation demands higher initial investment and operational complexity. On the contrary, single-room systems, with their compact design and manageable logistics, are easier to implement and operate, thus being a better fit for smaller healthcare facilities initiating their journey into particle therapy.

Cancer Type: Expanding usage of particle therapy for head & neck cancer owing to reduced risk on healthy tissue

Particle therapy, offering highly focused radiation, has brought about remarkable results in breast cancer management, especially for patients with recurring or aggressive forms of the disease. Particle therapy for head & neck cancer shows promising results due to the anatomical complexity of this region. The precise and high-dosage radiation from particle therapy minimizes the risk of excess radiation in healthy tissues around the tumor. Lung cancer, notorious for its resistance to traditional radiation therapy, has seen promising treatment outcomes through particle therapy. Particle therapy is considerably beneficial in treating pediatric cancers, reducing the long-term side effects usually associated with traditional radiation treatments. Prostate cancer treatment has been dramatically enhanced by particle therapy, given the highly effective and precise radiation techniques. In comparison, particle therapy has emerged as a new dawn in the field of head & neck cancer treatment, offering hope to patients battling various forms of the disease.

End-User: Significant role of particle therapy in hospitals & clinicals as they strive to provide high-quality care

Ambulatory surgery centers (ASCs) allow surgeons to deliver efficient, high-quality care at a lower cost. In particle therapy, these centers cater to instances where the cancer is well-defined and is treated in a few sessions. Hospitals and clinics offer more comprehensive care and cater to various cancer cases. They provide both proton and heavy ion therapies to treat a variety of cancers, including more complex issues. These institutions have large treatment facilities equipped with advanced particle therapy machines. Due to their nature of operation, ambulatory surgery centers embrace compact, streamlined designs best suited for less complex cases, striving for efficiency with limited space. Hospitals & clinics offer more robust treatment capabilities to manage various cases, from the simple to the complex.

Regional Insights

In America, the need for particle therapy has seen consistent growth. Technology innovation is frequent and heavily backed by both private and public organizations. This region holds the most significant market share due to extensive research activities and the rise of numerous startups funded by investors targeting therapy innovation. In the EMEA region, Europe exhibits formidable growth in particle therapy primarily due to the rising incidences of various cancer types and a growing elderly population at risk. Moreover, increased funding in healthcare from various governments and organizations, coupled with well-established healthcare facilities, allows for broader adoption of the technique. Middle Eastern and African countries also show promising growth, mainly due to rising healthcare expenditure and increased efforts to enhance healthcare infrastructure. In the APAC region, several economies are leading in adopting particle therapy for cancer treatment. Factors contributing to such progress include the increasing prevalence of cancer, rapid urbanization, and continually improving economic conditions. APAC offers a vast population base, which, combined with improving healthcare infrastructures and increasing government funding for cancer research and treatment, presents APAC as a fast-growing market for particle therapy.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Particle Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Particle Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Particle Therapy Market, highlighting leading vendors and their innovative profiles. These include Advanced Oncotherapy plc, B dot Medical Inc., Best Particle Therapy, Inc., BioSig Technologies Inc., Covenant Health, Danfysik A/S, Elekta AB, Hitachi, Ltd., IBA International, Koninklijke Philips N.V., Mevion Medical Systems, Mitsubishi Electric Corporation, New Mexico Cancer Center, Optivus Proton Therapy, Inc., P-Cure Ltd, ProTom International, Provision Healthcare, LLC, PTW Freiburg GmbH, SAH Global LLC, Shanghai APACTRON Particle Equipment Co., Ltd., Siemens Healthineers GmbH, Stantec Inc., Sumitomo Heavy Industries, Ltd., Toshiba Medical Systems Corporation, and Xstrahl Ltd..

Market Segmentation & Coverage

This research report categorizes the Particle Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Therapy Type
    • Heavy Ion Therapy
    • Proton Therapy
  • Component
    • Product
      • Cyclotrons
      • Synchrocyclotrons
      • Synchrotrons
    • Service
  • Configuration
    • Multi-room System
    • Single-room System
  • Cancer Type
    • Breast Cancer
    • Head & Neck Cancer
    • Lung Cancer
    • Pediatric Cancer
    • Prostate Cancer
  • End-User
    • Ambulatory Surgery Centers
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Particle Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Particle Therapy Market?

3. What are the technology trends and regulatory frameworks in the Particle Therapy Market?

4. What is the market share of the leading vendors in the Particle Therapy Market?

5. Which modes and strategic moves are suitable for entering the Particle Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Need for advanced therapies in cancer treatment
      • 5.1.1.2. Rise in adoption of particle therapy in clinical trials
      • 5.1.1.3. Growing number of particle therapy centers worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of particle therapy equipment and procedures, along with limited insurance coverage for particle therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing proton therapy research programs
      • 5.1.3.2. Technological advances in charged-particle therapy and enabling personalized cancer treatment strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Risk associated with the particle therapy radiation exposure
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Type: Consumer preference for proton therapy as it provides a reduced risk of damage to surrounding tissues
    • 5.2.2. Component: Rising utilization of product components for treating solid tumors near vital organs due to their high accuracy
    • 5.2.3. Configuration: Potential of a multi-room system for treating a larger number of patients concurrently
    • 5.2.4. Cancer Type: Expanding usage of particle therapy for head & neck cancer owing to reduced risk on healthy tissue
    • 5.2.5. End-User: Significant role of particle therapy in hospitals & clinicals as they strive to provide high-quality care
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Particle Therapy Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Heavy Ion Therapy
  • 6.3. Proton Therapy

7. Particle Therapy Market, by Component

  • 7.1. Introduction
  • 7.2. Product
  • 7.3. Service

8. Particle Therapy Market, by Configuration

  • 8.1. Introduction
  • 8.2. Multi-room System
  • 8.3. Single-room System

9. Particle Therapy Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Breast Cancer
  • 9.3. Head & Neck Cancer
  • 9.4. Lung Cancer
  • 9.5. Pediatric Cancer
  • 9.6. Prostate Cancer

10. Particle Therapy Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgery Centers
  • 10.3. Hospitals & Clinics

11. Americas Particle Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Particle Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Particle Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. IBA and PARTICLE Initiate FLASH Proton Therapy Research Partnership
    • 14.3.2. P-Cure Receives FDA Approval For Proton Therapy System For Treatment in Seated Position and Will Begin Treating Patients In Israel
    • 14.3.3. Terapet raises CHF 2.3 million for its next-generation cancer treatment technology
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio